NDAORALTABLET
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARUBI (rolapitant) is an oral small-molecule NK1 receptor antagonist approved in 2015 for prevention of chemotherapy-induced nausea and vomiting (CINV). It works by blocking substance P signaling in the central nervous system, a key pathway in CINV pathophysiology. The drug is administered as a tablet prior to chemotherapy in combination with 5-HT3 antagonists and corticosteroids.
$0.498MPart D
Peak3.3 years to LOEThe product is in peak commercial phase with modest Part D uptake (474 claims in 2023), suggesting a niche market with limited growth trajectory and likely a smaller dedicated team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)
Started Oct 2007
619 enrolled
Postoperative Nausea and Vomiting
Why This Matters for Your Career
Worked on VARUBI at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.